Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. / Stougaard, Elisabeth B.; Kristensen, Peter L.; Kielgast, Urd; Andersen, Henrik U.; Hamid, Yasmin; Gæde, Peter H.; Søndergaard, Esben; Dørflinger, Gry H.; Fjeldborg, Karen K.; Hansen, Klavs W.; Thomsen, Henrik H.; Al-Imar, Thuraya M.J.; Røder, Michael; Sridhar, Vikas S.; Cherney, David; Rossing, Peter; Persson, Frederik.
I: Diabetes & vascular disease research, Bind 19, Nr. 5, 2022, s. 14791641221130043.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis
AU - Stougaard, Elisabeth B.
AU - Kristensen, Peter L.
AU - Kielgast, Urd
AU - Andersen, Henrik U.
AU - Hamid, Yasmin
AU - Gæde, Peter H.
AU - Søndergaard, Esben
AU - Dørflinger, Gry H.
AU - Fjeldborg, Karen K.
AU - Hansen, Klavs W.
AU - Thomsen, Henrik H.
AU - Al-Imar, Thuraya M.J.
AU - Røder, Michael
AU - Sridhar, Vikas S.
AU - Cherney, David
AU - Rossing, Peter
AU - Persson, Frederik
PY - 2022
Y1 - 2022
N2 - BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.
AB - BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.
KW - diabetic ketoacidosis
KW - sglt2 inhibitors
KW - Type 1 diabetes
U2 - 10.1177/14791641221130043
DO - 10.1177/14791641221130043
M3 - Journal article
C2 - 36262089
AN - SCOPUS:85140415212
VL - 19
SP - 14791641221130043
JO - Diabetes and Vascular Disease Research
JF - Diabetes and Vascular Disease Research
SN - 1479-1641
IS - 5
ER -
ID: 323997300